Coronary plaque regression: role of low density lipoprotein-apheresis**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Barter, Philip J
EDITORIAL COMMENT
Coronary Plaque
Regression: Role of Low
Density Lipoprotein-Apheresis*
Philip J. Barter, MD, PHD
Adelaide, Australia
It has been proven beyond all reasonable doubt that lower-
ing the level of low density lipoprotein cholesterol (LDL-C)
reduces cardiovascular morbidity and mortality (1–7). This
benefit has been demonstrated in both a primary and
secondary prevention setting and has been observed in hard
end point and in regression studies. Benefits are apparent
both in subjects with hypercholesterolemia and in those
whose LDL-C levels are similar to the population mean.
There is now a consensus that the concentration of LDL-C
in high-risk patients should be reduced to target levels
shown in population studies to be associated with low rates
of coronary heart disease (CHD) (8). This consensus is
reflected in the National Cholesterol Education Program-
Adult Treatment Panel III (NCEP-ATP-III) guidelines,
which recommend that patients with manifest CHD should
have their LDL-C level reduced to 100 mg/dl (9).
The development of statin drugs has revolutionized the
management of patients with CHD and has made it
possible for the recommended LDL-C targets to be
achieved in many patients. These drugs have also made it
feasible to mount studies designed to compare the effects on
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CHD of moderate versus more aggressive lowering of
LDL-C. Large-scale end point studies investigating this
issue are currently underway and will provide answers over
the next few years. There are, however, several completed
studies reporting the effects of moderate versus aggressive
LDL-C lowering on the progression of arterial disease as
assessed by angiography or ultrasound.
One such study was the Postcoronary Artery Bypass
Graft Trial (10), which followed 1,351 patients who had
undergone bypass surgery 1 to 11 years previously. Partici-
pants had at least one patent vein graft as seen on angiog-
raphy. The lipid-lowering treatment was lovastatin supple-
mented, if necessary, with cholestyramine to generate two
groups. In one group the mean LDL-C was 93 to 97 mg/dl,
while in the other group the LDL-C was 132 to 136 mg/dl.
Angiography was repeated an average of 4.3 years after
commencing the therapy. The mean percentage of grafts
with progression of atherosclerosis was 27% for patients
whose LDL-C level was lowered with aggressive treatment
compared with 39% for those who received moderate
treatment; this difference was significant (p  0.001).
Furthermore, the rate of revascularization over four years
was significantly lower in the group whose LDL-C level was
lowered aggressively than in the group receiving moderate
treatment.
Another study investigating this issue was the Atorvasta-
tin Simvastatin Atherosclerosis Progression (ASAP) study
(11). Conducted in 325 patients with familial hypercholes-
terolemia, the study was designed to compare the effects of
moderate versus aggressive lowering of LDL-C in a popu-
lation with very high baseline levels of LDL-C. Participants
were randomized to receive daily doses of atorvastatin 80 mg
or simvastatin 40 mg. The primary end point was the
change in carotid intima media thickness (IMT) as deter-
mined by quantitative B-mode ultrasound. The LDL-C
level in the atorvastatin group was reduced 50.5% from a
baseline of 310 mg/dl to an on-trial level of 150 mg/dl,
whereas in the simvastatin group the LDL-C was reduced
41.2% from a baseline of 322 mg/dl to an on-trial level of
186 mg/dl. The high density lipoprotein cholesterol was
increased by about 13% in each group. Overall, IMT
decreased by a mean of 0.031 mm in the aggressively treated
group but increased 0.036 mm in the group in which the
LDL-C lowering was more moderate. This difference was
statistically significant. Regression of carotid IMT was seen
in 106 of the 160 subjects in the aggressively treated group
and in 65 of the 165 patients on moderate therapy. The
change in IMT correlated significantly with the percent of
LDL-C reduction.
Despite the impressive reduction in LDL-C concentra-
tion in the aggressively treated group in the ASAP study,
the on-trial concentration of LDL-C was still well above
the target level recommended in the NCEP-ATP-III
guidelines. The obvious question arises: Would regression
have been even greater had the LDL-C been reduced to
100 mg/dl? And if it would, how can such levels of
LDL-C be achieved in patients with familial hypercholes-
terolemia, many of whom have baseline LDL-C levels
300 mg/dl? As indicated in a study in this issue of the
Journal (12), one possible approach is to supplement drug
therapy with LDL-apheresis.
The study reported by Matsuzaki et al. (12) utilized a
combination of drugs and LDL-apheresis to lower the level
of LDL-C in patients with familial hypercholesterolemia.
This study included 19 patients, all of whom had manifest
CHD. All were receiving treatment with a statin (either
simvastatin 10 mg per day or pravastatin 20 mg per day) at
the time of commencing the study. In an attempt to achieve
much lower levels of LDL-C, all patients were recom-
mended to receive LDL-apheresis in addition to the drug
therapy. This option was taken up by 12 of the subjects,
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with 11 of the 12 completing the study. The remaining
seven subjects who declined LDL-apheresis continued to
take their lipid-lowering medication and were followed as a
control group.
The LDL-apheresis was performed using an automated
system in which plasma was passed through two columns
containing dextran sulfate covalently bound to cellulose
beads. The procedure was conducted biweekly in an outpa-
tient clinic, with an amount of plasma 1.5 times the
plasma volume being treated at each session. This procedure
resulted in a reduction of the plasma total cholesterol to
100 mg/dl immediately after the LDL-apheresis.
The group receiving medication alone had an LDL-C
level that did not change over the year of follow-up
(174 mg/dl at the beginning and 181 mg/dl at one year),
while the group receiving LDL-apheresis in addition to the
drug therapy had a substantial further reduction in concen-
tration of LDL-C. Because the rebound after LDL-
apheresis was not linear, the LDL-C concentration in the
apheresis group was expressed as a time-averaged value.
According to this method of expression, the concentration
of LDL-C was reduced by LDL-apheresis from a baseline
level of 213 mg/dl to a treatment level of 140 mg/dl.
Coronary angiography was performed at baseline and
again one year later to determine the minimum lumen
diameter (MLD). Intravascular ultrasound of coronary ar-
teries was also conducted at baseline and after one year to
determine the plaque area, the lumen area and the vessel
area. The MLD was significantly increased in the LDL-
apheresis group but was unchanged in the medication-only
group. The plaque area was significantly decreased in the
LDL-apheresis group but significantly increased in the
group receiving medication alone. Lumen areas and vessel
areas did not change significantly during the year of study in
either group. The combined use of angiography to assess
lumen diameter and intravascular ultrasound to define
changes in the plaque is a strength of the study by
Matsuzaki et al. (12).
The study provides information of interest and potential
importance, although the conclusions are limited by defi-
ciencies in the experimental design. For example, the
sample size was small and the subjects were not randomly
allocated to the two groups. Nor were the two groups
matched in terms of severity of coronary artery disease or
plasma lipid levels, although the fact that the LDL-
apheresis group had higher LDL-C levels and displayed
more severe coronary atherosclerosis at baseline would have
masked rather than exaggerated the possible effects of the
treatment. Despite the problems with experimental design,
the Matsuzaki et al. (12) study does provide evidence of a
benefit of LDL-apheresis in patients with familial hyper-
cholesterolemia.
The superiority of LDL-apheresis plus medication over
medication alone adds to a growing body of evidence that
the benefits of lowering the level of LDL-C are related to
the magnitude of the reduction. To this extent, the results of
the Matsuzaki et al. (12) study support the conclusion
drawn from the ASAP study (11), which used two regimens
of drug therapy to compare the effects of aggressive versus
moderate LDL-C lowering in hypercholesterolemic pa-
tients.
The investigation by Matsuzaki et al. (12) is not the first
to suggest cardioprotective effects of LDL-apheresis.
Mabuchi et al. (13) reported a six-year nonrandomized
study of 130 patients with familial hypercholesterolemia in
whom 87 received cholesterol-lowering drugs alone, while
43 received drug therapy plus LDL-apheresis. Greater
reductions in LDL-C and lower on-trial LDL-C levels in
the apheresis group were associated with a 72% reduction in
the coronary event rate (defined as a composite of nonfatal
myocardial infarction, revascularization and CHD death).
Other reports have suggested benefits of LDL-apheresis
(14,15), although these studies were not designed to com-
pare the apheresis with other modes of therapy.
If confirmed, the study reported by Matsuzaki et al. (12)
supports a role for LDL-apheresis in patients with familial
hypercholesterolemeia in whom levels of LDL-C remain
above target values despite aggressive lipid-lowering medi-
cation. However, the possible advantages of LDL-apheresis
have to be weighed against the intrusive nature and the cost
of the procedure. It will also need to be demonstrated that
the benefits of LDL-apheresis are substantial when used in
the setting of a much more aggressive drug regimen than the
relatively low doses of statin drugs used in the study
reported by Matsuzaki et al. (12). Whether LDL-apheresis
will have an additional effect when combined with the
highest doses of the newer superstatins remains to be
determined. Such a study will need to be conducted before
drawing conclusions about the role of LDL-apheresis as
therapy to lower the concentration of LDL-C in patients
with familial hypercholesterolemia.
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